Related references
Note: Only part of the references are listed.Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen
Karolina Aragon-Gawinska et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2020)
Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps
Teresa Gidaro et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2019)
Newborn screening for SMA in Southern Belgium
Francois Boemer et al.
NEUROMUSCULAR DISORDERS (2019)
Nusinersen in later-onset spinalmuscular atrophy Long-term results from the phase 1/2 studies
Basil T. Darras et al.
NEUROLOGY (2019)
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo et al.
NEUROMUSCULAR DISORDERS (2019)
Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives
Tamara Dangouloff et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2019)
Pilot study of population-based newborn screening for spinal muscular atrophy in New York state
Jennifer N. Kraszewski et al.
GENETICS IN MEDICINE (2018)
CLINICAL TRIAL OF L-CARNITINE AND VALPROIC ACID IN SPINAL MUSCULAR ATROPHY TYPE I
Kristin J. Krosschell et al.
MUSCLE & NERVE (2018)
Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safety
John J. Weaver et al.
PEDIATRIC RADIOLOGY (2018)
Nusinersen for SMA: expanded access programme
Michelle A. Farrar et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
Richard S. Finkel et al.
NEUROMUSCULAR DISORDERS (2018)
Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases
Maite Calucho et al.
NEUROMUSCULAR DISORDERS (2018)
Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
Eugenio Mercuri et al.
NEUROMUSCULAR DISORDERS (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
Hasane Ratni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy
Kevin A. Strauss et al.
JOURNAL OF PEDIATRIC ORTHOPAEDICS (2018)
Nusinersen in patients older than 7 months with spinal muscular atrophy type 1 A cohort study
Karolina Aragon-Gawinska et al.
NEUROLOGY (2018)
Myostatin expression is a reliable and quantifiable biomarker to monitor dose-dependent drug response in muscular dystrophy
J. Dumonceaux et al.
NEUROMUSCULAR DISORDERS (2018)
Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study
Aurelie Chabanon et al.
PLOS ONE (2018)
How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy
N. N. Singh et al.
GENE THERAPY (2017)
Presymptomatic Diagnosis of Spinal Muscular Atrophy Through Newborn Screening
Yin-Hsiu Chien et al.
JOURNAL OF PEDIATRICS (2017)
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
Enrico Bertini et al.
LANCET NEUROLOGY (2017)
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience
Sonia Messina et al.
NEUROMUSCULAR DISORDERS (2017)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
Virginie Mariot et al.
NATURE COMMUNICATIONS (2017)
Diverse role of survival motor neuron protein
Ravindra N. Singh et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2017)
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Richard S. Finkel et al.
LANCET (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Disease burden of spinal muscular atrophy in Germany
Constanze Klug et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
The economic burden of spinal muscular atrophy
Edward P. Armstrong et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice
James Palacino et al.
NATURE CHEMICAL BIOLOGY (2015)
SMA VALIANT TRIAL: A PROSPECTIVE, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF VALPROIC ACID IN AMBULATORY ADULTS WITH SPINAL MUSCULAR ATROPHY
John T. Kissel et al.
MUSCLE & NERVE (2014)
Observational study of spinal muscular atrophy type I and implications for clinical trials
Richard S. Finkel et al.
NEUROLOGY (2014)
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Nikolai A. Naryshkin et al.
SCIENCE (2014)
Spinal muscular atrophy: going beyond the motor neuron
Gillian Hamilton et al.
TRENDS IN MOLECULAR MEDICINE (2013)
Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of > 72 400 specimens
Elaine A. Sugarman et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2012)
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model
Yimin Hua et al.
NATURE (2011)
Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN
Kevin D. Foust et al.
NATURE BIOTECHNOLOGY (2010)
Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy
T. -H. Chen et al.
NEUROLOGY (2010)
Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy
Chiara F. Valori et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
A Positive Modifier of Spinal Muscular Atrophy in the SMN2 Gene
Thomas W. Prior et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2009)
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Kevin D. Foust et al.
NATURE BIOTECHNOLOGY (2009)
Ramblings in the history of spinal muscular atrophy
Victor Dubowitz
NEUROMUSCULAR DISORDERS (2009)
Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in Transgenic mice
Yimin Hua et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Consensus statement for Standard of Care in Spinal Muscular Atrophy
Ching H. Wang et al.
JOURNAL OF CHILD NEUROLOGY (2007)
The Hammersmith functional score correlates with the SMN2 copy number:: A multicentric study
F. D. Tiziano et al.
NEUROMUSCULAR DISORDERS (2007)
Pilot trial of phenylbutyrate in spinal muscular atrophy
E Mercuri et al.
NEUROMUSCULAR DISORDERS (2004)
A phase 1 trial of Riluzole in spinal muscular atrophy
BS Russman et al.
ARCHIVES OF NEUROLOGY (2003)
Pilot trial of albuterol in spinal muscular atrophy
M Kinali et al.
NEUROLOGY (2002)
Share Paper
